Newsroom

latest news from ose
and across our portfolio

Featured News

Oxford Spinout Oxford Semantic Technologies acquired by Samsung Electronics
Oxford Spinout Oxford Semantic Technologies acquired by Samsung ElectronicsArticle links to www.oxionics.com
Oxford Ionics breaks global quantum performance records
Oxford Ionics breaks global quantum performance records
Times Commentary: Science innovation must be at the heart of government action
Times Commentary: Science innovation must be at the heart of government actionArticle links to www.beacontx.com
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesArticle links to www.prnewswire.com
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptography
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptographyArticle links to www.globenewswire.com
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raises
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raisesArticle links to www.businesswire.com
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group

All News

Portfolio NewsNucleome TherapeuticsNucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune diseasePortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Mark Bodmer as Chief Executive OfficerPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading expertsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific OfficerPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dr Russell Greig as Non-Executive Chair of the BoardPortfolio NewsNucleome TherapeuticsNucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicinesPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dina Anderson as Vice President of OperationsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Phil Boyd as Chief Financial OfficerPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Nigel Clark as Chief Business OfficerPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces formation of advisory boardPortfolio NewsNucleome TherapeuticsGene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome TherapeuticsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its BoardPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature